Since TMZ is the first-line chemotherapy drug, and the mutation of ATRX resulted in the most commonly abnormal heredity in gliomas, Han Bo et al. knocked out ATRX to explore the influence of ARTX on TMZ resistance [72]. The gene discussed is ATRX; the disease is central nervous system cancer.